Abstract
The effect of aminoguanidine (AG) on structural abnormalities in optic nerve fibers was evaluated in streptozotocin-induced diabetic rats. Morphometry of myelinated optic nerve fibers showed a partial amelioration on the reduction of the axon size but complete preservation of myelin size with low dose (25 mg kg-1 body weight) AG treatment. High dose (100 mg kg-1 body weight) AG completely prevented myelinated nerve fiber atrophy. These findings indicated that nonenzymatic glycation contributes to the development of optic nerve changes in diabetic rats.
Copyright 1998 Elsevier Science B.V. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Body Weight
-
Diabetes Mellitus, Experimental / complications*
-
Diabetic Neuropathies / drug therapy*
-
Diabetic Neuropathies / enzymology
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / pharmacology*
-
Glycation End Products, Advanced / antagonists & inhibitors
-
Glycation End Products, Advanced / metabolism
-
Guanidines / pharmacology*
-
Male
-
Nerve Fibers, Myelinated / drug effects
-
Nerve Fibers, Myelinated / metabolism
-
Optic Nerve Diseases / drug therapy*
-
Optic Nerve Diseases / enzymology
-
Rats
-
Rats, Wistar
Substances
-
Enzyme Inhibitors
-
Glycation End Products, Advanced
-
Guanidines
-
pimagedine